Ingenia Therapeutics, a clinical-stage biotechnology company pioneering next-generation vascular-targeted therapies, today announced that it has been nominated for the Prix Galien USA and the inaugural Prix Galien Korea, both in the Best Startup category by The Galien Foundation. The Galien Foundation is the premier global institution recognizing and awarding outstanding achievements of innovators in life sciences.

The dual recognition arrives alongside a defining milestone for Ingenia: its initial public offering on the KOSDAQ on August 18th. Together, the nominations underscore the global momentum behind the company’s proprietary TIE-body and LCIDEC platforms, which are built on a fundamental breakthrough in vascular biology, the direct, ligand-independent activation of the TIE2 pathway to restore the vascular barrier.

“To be recognized in both the United States and Korea is a tremendous honor and a reflection of our team’s commitment to global innovation,” said Sangyeul Han, PhD, CEO of Ingenia Therapeutics. “As a US company listed on KOSDAQ, we are proud to bridge both markets, and these nominations affirm the potential of our direct TIE2 activation technology to meaningfully advance the treatment of vascular-driven diseases, and they strengthen our commitment to bringing these therapies to patients faster.”

Ingenia’s pipeline is anchored by two clinical-stage programs: MK-8748 (Tiespectus), an investigational bispecific antibody (Anti-VEGF/TIE2) advancing into Phase 3 for patients with neovascular age-related macular degeneration (nAMD) and patients with diabetic macular edema (DME) through its collaboration with Merck (known as MSD outside of the US and Canada); and IGT-303, progressing through Phase 1/2a trials across Australia, New Zealand, and South Korea for chronic kidney disease (CKD).

About Ingenia Therapeutics

Ingenia Therapeutics is a clinical-stage biotechnology company focused on developing first-in-class therapies that restore the vascular stability. Headquartered in Watertown, MA, USA, with operations in South Korea and Australia, the company leverages its expertise in antibody engineering to target the TIE2 pathway across ophthalmology, nephrology, oncology and other high-value therapeutic areas, including CNS and Cardiovascular & Pulmonary diseases.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of applicable securities laws, including, without limitation, statements regarding Ingenia Therapeutics’ business strategy, research and development plans, clinical trial initiation and completion timelines, regulatory submissions and approvals, commercialization plans, anticipated milestones, projected financial performance, expected revenue, including potential milestone, royalty, or other payments from existing or future collaborations with Merck, EyeBio, or other partners.

Forward-looking statements are based on the Company’s current expectations, assumptions, estimates, and projections and are subject to numerous risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation: risks inherent in the discovery, development, and commercialization of pharmaceutical product candidates; uncertainty of preclinical data and clinical trial results; the timing, cost, and outcome of regulatory review by applicable authorities; the Company’s ability to obtain and maintain intellectual property protection; manufacturing and supply chain risks; competition; the Company’s ability to successfully establish, maintain, and realize anticipated benefits from strategic collaborations, including collaborations with Merck and EyeBio; the amount and timing of any milestone, royalty, or other payments under such agreements; the Company’s dependence on third parties; the need for additional capital and the availability of financing; and risks related to general market, economic, and industry conditions.

There can be no assurance that any product candidate will successfully complete development, obtain regulatory approval, achieve commercial success, or generate revenue. Likewise, there can be no assurance that anticipated revenue from collaborations will be realized as expected, or at all. For purposes of the Financial Investment Services and Capital Markets Act of Korea (“FSCMA”), these forward-looking statements are provided in good faith based on information currently available to the Company and are subject to change due to uncertainties and risks beyond the Company’s control. This press release is not an offer to sell or a solicitation of an offer to buy securities in Korea or in any other jurisdiction. Any offering of securities in Korea will be made only pursuant to a securities registration statement filed with the Financial Services Commission and in compliance with applicable KRX listing regulations. Ingenia Therapeutics undertakes no obligation to update or revise any forward-looking statements, except as required by applicable law.

Media gallery

About The Author
Business Wire